Please use this identifier to cite or link to this item:
Title: Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): A trial protocol for a randomised clinical trial
Authors: Mo, Yin 
West, Timothy Eoin
MacLaren, Graeme 
Booraphun, Suchart
Li, Andrew Yunkai 
Kayastha, Gyan
Lau, Yie Hui
Chew, Yin Tze
Chetchotisakd, Ploenchan
Tambyah, Paul Anantharajah 
Limmathurotsakul, Direk
Cooper, Ben
Keywords: infectious diseases
intensive & critical care
statistics & research methods
Issue Date: 1-May-2021
Publisher: BMJ Publishing Group
Citation: Mo, Yin, West, Timothy Eoin, MacLaren, Graeme, Booraphun, Suchart, Li, Andrew Yunkai, Kayastha, Gyan, Lau, Yie Hui, Chew, Yin Tze, Chetchotisakd, Ploenchan, Tambyah, Paul Anantharajah, Limmathurotsakul, Direk, Cooper, Ben (2021-05-01). Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): A trial protocol for a randomised clinical trial. BMJ Open 11 (5) : e050105. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Introduction Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in intensive care units (ICUs). Using short-course antibiotics to treat VAP caused by Gram-negative non-fermenting bacteria has been reported to be associated with excess pneumonia recurrences. The "REducinG Antibiotic tReatment Duration for Ventilator-Associated Pneumonia"(REGARD-VAP) trial aims to provide evidence for using a set of reproducible clinical criteria to shorten antibiotic duration for individualised treatment duration of VAP. Methods and analysis This is a randomised controlled hierarchical non-inferiority-superiority trial being conducted in ICUs across Nepal, Thailand and Singapore. The primary outcome is a composite endpoint of death and pneumonia recurrence at day 60. Secondary outcomes include ventilator-associated events, multidrug-resistant organism infection or colonisation, total duration of antibiotic exposure, mechanical ventilation and hospitalisation. Adult patients who satisfy the US Centers for Disease Control and Prevention National Healthcare Safety Network VAP diagnostic criteria are enrolled. Participants are assessed daily until fever subsides for >48 hours and have stable blood pressure, then randomised to a short duration treatment strategy or a standard-of-care duration arm. Antibiotics may be stopped as early as day 3 if respiratory cultures are negative, and day 5 if respiratory cultures are positive in the short-course arm. Participants receiving standard-of-care will receive antibiotics for at least 8 days. Study participants are followed for 60 days after enrolment. An estimated 460 patients will be required to achieve 80% power to determine non-inferiority with a margin of 12%. All outcomes are compared by absolute risk differences. The conclusion of non-inferiority, and subsequently superiority, will be based on unadjusted and adjusted analyses in both the intention-to-treat and per-protocol populations. Ethics and dissemination The study has received approvals from the Oxford Tropical Research Ethics Committee and the respective study sites. Results will be disseminated to patients, their caregivers, physicians, the funders, the critical care societies and other researchers. Trial registration number NCT03382548. © 2021 BMJ Publishing Group. All rights reserved.
Source Title: BMJ Open
ISSN: 2044-6055
DOI: 10.1136/bmjopen-2021-050105
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1136_bmjopen-2021-050105.pdf400.46 kBAdobe PDF




checked on Mar 26, 2023

Page view(s)

checked on Mar 30, 2023

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons